{"id":"NCT01610700","sponsor":"Jazz Pharmaceuticals","briefTitle":"An Investigation of Delta-9-tetrahydrocannabinol (THC) and Cannabidiol (CBD) in Multiple Sclerosis Patients","officialTitle":"Double Blind, Randomised, Parallel Group, Placebo Controlled Trial of a Combination of THC and CBD in Patients With Multiple Sclerosis, Followed by an Open Label Assessment and Study Extension","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2001-05","primaryCompletion":"2002-07","completion":"2002-07","firstPosted":"2012-06-04","resultsPosted":"2012-09-19","lastUpdate":"2023-01-12"},"enrollment":160,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Multiple Sclerosis"],"interventions":[{"type":"DRUG","name":"GW-1000-02","otherNames":["Sativex"]},{"type":"DRUG","name":"Placebo","otherNames":[]}],"arms":[{"label":"GW-1000-02","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"A study to compare the efficacy of GW-1000-02 \\[named Sativex® in Canada and also named Sativex® Oromucosal Spray\\] with placebo in relieving five key symptoms of Multiple Sclerosis after six weeks of therapy.","primaryOutcome":{"measure":"Change From Baseline in Composite Primary Impairment Visual Analogue Scale Score at the End of 6 Weeks of Treatment","timeFrame":"baseline and 6 weeks","effectByArm":[{"arm":"GW-1000-02","deltaMin":-25.32,"sd":23.42},{"arm":"Placebo","deltaMin":-19.32,"sd":27.02}],"pValues":[{"comp":"OG000 vs OG001","p":"0.124"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":12,"exclusionCount":14},"locations":{"siteCount":1,"countries":["United Kingdom"]},"refs":{"pmids":["15327042"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":80},"commonTop":["Dizziness","Headache NOS","Application site pain","Fatigue","Oral discomfort"]}}